

October 14-18, 2024 | Athens, Greece
www.bioemtech.com

4th Annual

BPW

**BIOEMTECH's
Preclinical Workshop**


Once per year, in BIOEMTECH Laboratories, we open our doors and meet with the Drug Discovery & Targeted Radioligand Therapy community, to discuss methodologies & share experience & knowledge. We welcome renowned speakers from Academia & Industry and explore optimal procedures in our boutique GLP labs.



BPW's 2024 Partners:



A warm welcome



Welcome to the **4th Preclinical Models Imaging Workshop!**

After being actively involved in the **Drug and Radioligand Therapy** field, for more than 15 years, we decided to create the Workshop that we wish we had access to, during this journey. We have been active participants of many workshops so far and hope to offer a **unique networking and knowledge meeting, that leaves participants with a deep understanding and realisation of the major and most novel issues of the field**, as well as possible **new collaborations and contacts**.

Main workshop points:

- Targeted Radioligand Therapy (**TRT**), alpha particles & dosimetry
- Molecules & Target expression in drug discovery
- Colorectal cancer (SW480 & HT29), heart infraction & endometriosis Models
- Radiochemistry & QCs towards *in vivo* studies
- *In vivo* imaging technologies (SPECT/PET/CT/optical/US/MRI) & applications
- Laboratory Facility Management, GLP & SOPs

Hands-on session on:

- Radiochemistry, model preparation, *in vivo* imaging and post processing

We hope to see you in Athens soon and dive into meaningful discussions!

Past attendees have said:

“It was a very enriching experience in which I could interact with colleagues from so many different fields.”

**Pre-Clinical Research Associate
Precirix (Belgium)**


“Exceedingly well-organized workshop. An essential prerequisite for anyone starting out in this field or for established people that want to expand their scope of knowledge.”

**Manufactures' representative
for imaging
Ragona Scientific (NY, USA)**

“Thank you for the very well-arranged course. I truly enjoyed it! Even though I have been working with animals for 15 years, I still had some aha-moments!”

**Clinical Development Manager
SPAGO Nanomedical (Sweden)**

Our Speakers & Panelists



Jeff Norenberg
Co-Founder &
Executive Officer
iSeek Biopharma



Jacob Hesterman
Chief Data Officer
Ratio Therapeutics



Marion Malenge
Senior Scientist &
Program Lead
ArtBio



Sujiet Puthenveetil
Director
AstraZeneca



Anne Bredenbeck
Senior Scientist
Radiopharmaceutical Technologies
3B Pharmaceuticals



Janke Kleynhans
Postdoctoral Scientist
KU Leuven




Olof Eriksson
Chief Scientific Officer
Antaros Tracer



Justin Jeffery
Co-Founder & Chief
Innovation Officer
Phantech

Our Speakers & Panelists



Ingrid Yao Mattisson
Clinical Development
Manager
Spago Nanomedical



Thomas Wanek
Imaging Scientist
**Medizinische
Universität Wien**



Alice Zoso
Researcher
Politecnico di Torino



Mattia Asti
Radiochemist Director
AUSL-IRCCS



Irving Coy Allen
Associate Professor-
Consultant
ACM



Felix Gremse
CEO
Gremse-IT



Syed Nuruddin
Senior Researcher
**Norsk medisinsk
syklotron senter**




Michel Afargan
Head Drug Developments &
Radiopharmaceutical Strategies
Starget Pharma



Monique Bernsen
Assistant Professor
Erasmus MC

Our Speakers & Panelists



Federico Maisano
Principal Scientist
Bracco Imaging



Pradip Chaudhari
Scientific Officer
ACTREC



Panagiotis Papadimitroulas
Co-Founder, Head of Software
BIOEMTECH



Thodoris Karampelas
Partner, CSO
**BIOEMTECH
Laboratories**



Argyro Zacharioudaki
Designated Veterinarian &
In-vivo Research Consultant
**BIOEMTECH
Laboratories**



Sophia Sarpaki
Project Manager
**BIOEMTECH
Laboratories**




Eliza Lambidis
R&D Radiochemist
**BIOEMTECH
Laboratories**



Antonis Skliris
In Vitro/ Cell Lab Manager
**BIOEMTECH
Laboratories**

Workshop day 1

Monday 14 October



09:00 Registration and welcome coffee

**George Loudos
& Maritina Rouchota**

CEO & COO

BIOEMTECH Laboratories

09:15

Workshop opening

All participants

09:45

Participants roundtable

10:30-11:00 Coffee break

Imaging Modalities Session

Syed Nuruddin

Senior Researcher

Norsk medisinsk syklotron senter

11:00

Imaging modalities in drug development evaluation

Justin Jeffery

Co-Founder & Chief Innovation Officer

Phantech

11:30

Imaging & Radiotherapy modalities in preclinical research facilities

Thomas Wanek

Imaging Scientist

Medizinische Universität Wien

12:00

How to perform PET/CT image post processing

Moderator: **Pradip Chaudhari**

Scientific Officer, **ACTREC**

Participants: Session speakers

12:30

Panel discussion “Imaging modalities and selection”

13:30-15:00 Lunch and Networking break

Non oncology models Session

Ingrid Yao Mattisson

Clinical Development Manager

Spago Nanomedical

15:00

Clinical data and preclinical models of endometriosis

Alice Zoso

Researcher

Politecnico di Torino

15:30


Preclinical validation of in vitro and in vivo models of heart infarction

17:00 Opening ceremony & drinks

TBA

Workshop day 2

Tuesday 15 October



09:00 Registration and welcome coffee

Isotopes & Cells Session

Mattia Asti Radiochemist Director, AUSL-IRCCS	09:30	Chelators for the next generation of theranostic soft radiometals
Marion Malenge Senior Scientist & Program Lead, ArtBio	10:00	A close look to therapeutic isotopes
Antonis Skliris In Vitro Lab Manager, BIOEMTECH Laboratories	10:30	<i>In vitro</i> assays towards <i>in vivo</i> studies

11:00-11:30 Coffee break

Radiolabelling Session

Janke Kleynhans Postdoctoral Scientist, KU Leuven	11:30	Alpha emitting isotopes
Sofia Sarpaki Project Manager & Lead Radiochemist BIOEMTECH Laboratories	12:00	Radiolabelling towards <i>in vivo</i> studies
Moderator: Eliza Lambidis , R&D Radiochemist, BIOEMTECH Laboratories Participants: All session speakers	12:30	Panel discussion "Isotope selection"

13:30-15:00 Lunch and Networking break

Dosimetry Session

Panagiotis Papadimitroulas Co-Founder, Head of Software, BIOEMTECH	15:00	Computational dosimetry approaches for preclinical applications
Felix Gremse CEO, Gremse-IT	15:30	Dosimetry through sequential imaging acquisitions


Closing lecture

Michel Afargan Head Drug Developments & Radiopharmaceutical Strategies Target Pharma	16:00	Preclinical perspectives in nuclear oncology
---	-------	--

17.30 Guided Laboratory tour

Workshop day 3

Wednesday 16 October



09:00

Bus transfer from The Golden Age Hotel to BIOEMTECH Laboratories

Dimitris Anestis

Medical imaging data scientist

BIOEMTECH Laboratories

09:30

Radiation protection

10:00-10:30 Coffee break

Hands-On Session

2 hrs (20 minutes per group)

Antonis Skliris

In Vitro/ Cell Lab Manager

BIOEMTECH Laboratories

Model development

Eliza Lambidis

R&D Radiochemist

BIOEMTECH Laboratories

Radio-compound preparation

Argyro Zacharioudaki

Designated Veterinarian & In-vivo Research
Consultant

BIOEMTECH Laboratories

Anaesthesia preparation

Compound administration

Sofia Lagoumtzi

Applications Specialist

BIOEMTECH Instruments

Image acquisition

Felix Gremse

CEO

Gremse-IT GmbH

Post processing

13:00-14:30 Lunch and Networking break

Social events


18:30 Get together snacks and drinks

20:30 Dinner Visit at National Observatory of Athens

(Lofos Nymphon, 11810, Athens)

Workshop day 4

Thursday 17 October



09:00 Registration and welcome coffee

Jeff Norenberg

Co-Founder & Executive Officer

iSeek Biopharma

09:30

Keynote: Molecules in drug discovery

10:15-10:45 Coffee break

Molecules Session

Anne Bredenbeck

Senior Scientist Radiopharmaceutical Technologies

3B Pharmaceuticals

10:45

Radiolabelled peptides for diagnosis and therapy

Federico Maisano

Principal Scientist

Bracco Imaging

11:15

Small molecules as radiopharmaceutical vectors

Moderator: **Jeff Norenberg**, Co-Founder & Executive Officer, **iSeek Biopharma**

Participants: Session speakers

& **Sujiet Puthenveetil**, Director, **AstraZeneca**

11:45

Panel discussion "Choosing the right molecule"

12:15-13:45 Lunch and Networking break

Regulatory and operating aspects of preclinical/clinical studies

Irving Coy Allen

Associate Professor-Consultant

ACM

13:45

Preclinical trial requirements for clinical studies

Monique Bernsen

Assistant Professor

Erasmus MC

14:15

Standard Operating Procedures (SOPs)

Argyro Zacharioudaki, Designated Veterinarian & In-vivo Research Consultant, **BIOEMTECH**

Laboratories

14:45

Regulatory aspects of preclinical studies

Moderator: **Argyro Zacharioudaki**, Designated Veterinarian & In-vivo Research Consultant,

BIOEMTECH Laboratories

Participants: Session speakers


15:15

Panel discussion "GLP & procedures"

17.00 Guided Laboratory tour

Workshop day 5

Friday 18 October



09:00 Registration and welcome coffee

Theodoros Karamelas
CSO
BIOEMTECH Laboratories

09:30

Oncology models & therapy options

10:15-10:45 Coffee break

Molecules Session

Theodoros Karamelas
CSO
BIOEMTECH Laboratories

10:45

Keynote: Molecular targets in drug discovery

Jacob Hesterman
Chief Data Officer
Ratio Therapeutics

11:15

Imaging & dosimetry considerations for different targets

Olof Eriksson
Chief Scientific Officer
Antaros Tracer

11:45

PET imaging endpoints for fibrosis and inflammation in drug development

Moderator: **Theodoros Karamelas**,
CSO, **BIOEMTECH Laboratories**
Participants: Session speakers
& **Jeff Norenberg**, Co-Founder &
Executive Officer, **iSeek Biopharma**

12:15

Panel discussion "Targets & therapies"


George Loudos & Maritina Rouchota
CEO & COO
BIOEMTECH Laboratories

13:30

Closing & Feedback Session

Closing Ceremony & Farewell Drinks

Our Speakers & Panelists



○ **Jeff Norenberg**, *Co-Founder & Executive Officer iSeek Biopharma*



With over 30 years of experience to his credit, Dr. Norenberg began his career as director of Keck-UNM Small-Animal Imaging Resource at the University of New Mexico Health Sciences Center. He continued at the College of Pharmacy New Mexico Center for Isotopes in Medicine as associate director before being appointed to the role of professor of anesthesiology and critical care medicine at the School of Medicine. He contributed to Invicro as vice president of chemistry from 2020 to 2021. He was active as chief scientific officer at Clarity Pharmaceuticals from 2022 to 2023. Concurrent to these postings, he served as executive director and chairman at the National Association of Nuclear Pharmacies since 2002. Before embarking on his professional path, Dr. Norenberg pursued an education at the University of Nebraska-Lincoln where he earned a Bachelor of Science in biology and biological sciences in 1986. He continued his studies at the University of New Mexico, graduating with a Bachelor of Science in pharmacy in 1989 and a Master of Science in pharmaceutical sciences in 1991. At the University of Washington, he completed a Doctor of Pharmacy in 2001 before concluding his academic efforts at Erasmus University Rotterdam and obtaining a PhD in molecular medicine in 2013. He holds certifications in organizational leadership from the Harvard T.H. Chan School of Public Health and as a Nuclear Pharmacist from the Board of Pharmacy Specialties.

○ **Jacob Hesterman**, *Chief Data Officer Ratio Therapeutics*




Holds a B.Sc. in Optics from the University of Rochester and an M.Sc. and PhD in Optical Sciences from the University of Arizona. After graduate school, he joined Bioscan, working in R&D and as the product manager for the NanoSPECT/CT system. He later spent a year as a Visiting Scientist in the Frangioni laboratory at Beth Israel Deaconess Medical Center in Boston, MA. Dr. Hesterman was a founding member of Invicro, where he built the Image Analysis group. Later, he became Chief Technology Officer for Realm IDx, leading the imaging, software, and bioinformatics groups across Invicro & Ambry Genetics. Currently, Dr. Hesterman is the Chief Data Officer for Ratio Therapeutics where he is responsible for imaging, data, and dosimetry across their preclinical and clinical programs. Outside of work, Dr. Hesterman is an avid birder & council member of Mass Audubon and coaches his daughters' soccer teams.

○ **Marion Malenge**, *Senior Scientist & Program Lead ArtBio*



Experienced senior researcher with over 9 years' experience in the biotech industry specializing on the development of radiopharmaceuticals for cancer treatment. Currently, she is working as Senior Scientist, and Head of *in vivo* at ARTBIO AS, Norway. She holds a PhD in Medicine and Health Sciences from the University of Oslo where she focused on preclinical development of radioimmunotherapies. She has worked in different scientific capacities in multiple Norway based radiopharmaceutical companies.

Our Speakers & Panelists



○ **Sujiet Puthenveetil**, *Director AstraZeneca*



He spearheads a multidisciplinary team dedicated to pioneering technologies in targeted delivery for oncology and other therapeutic areas. He oversees highly skilled teams of protein engineers, analytical chemists, radiochemists, medicinal chemists, and bioconjugation scientists, focused on advancing antibody-drug conjugates (ADCs) and radioligand therapeutics (RLTs) to the clinic. With over 14 years of industry experience, Sujiet brings a wealth of expertise to his current role. As a senior leader, Sujiet co-chairs the Biological Engineering team, shaping the strategy and management of pipeline assets for the Oncology Targeted Delivery Unit. Before joining AstraZeneca, Sujiet served as a Principal Scientist at AbbVie, where his team delivered several ADCs for autoimmune indications, including ABBV-154. His career began at Pfizer, where he worked on innovative site-specific technologies for ADCs, such as PF-06804103. Sujiet earned his Ph.D. from the University of Utah and completed his postdoctoral research at the Massachusetts Institute of Technology.

○ **Anne Bredenbeck**, *Senior Scientist Radiopharmaceutical Technologies 3B Pharmaceuticals GmbH*




On 2001 is finished her studies of Biology in Frankfurt and Freiburg, Germany. On 2002 she begun her PhD thesis in the Clinical Research Group "Tumour Immunology" at the Department of Dermatology, Charité-Universitätsmedizin-Berlin. She graduated on 2006 with a PhD in Tumor immunology at "Freie Universität, Berlin". From 2007-2009 she performed her Postdoc at Bayer HealthCare in the field of immunology and dermatology and 2009-2012 was the Laboratory Head at Bayer Healthcare, leading and coordinating interdisciplinary projects in early preclinical research on gynaecological therapies (endometriosis and leiomyoma). Since 2012 she is working as Senior Scientist at 3B Pharmaceuticals, responsible for planning, conducting, analysing and monitoring internal and external *in vivo* studies. She has a strong background in *in vivo* imaging using SPECT/CT and PET/CT. Accountable for animal husbandry and animal testing.

○ **Janke Kleynhans**, *Postdoctoral Scientist KU Leuven*



Post-Doctoral Research fellow at KU Leuven (Belgium) funded by the prestigious Fonds Wetenschappelijk Onderzoek Senior Postdoctoral Grant. She was employed as a Clinical Radiopharmacist/Researcher at Pretoria University (2018-2020) and Stellenbosch University (2021-2022) in South Africa. She has a PhD in Pharmaceutical Sciences (2018), Master's degrees in Pharmaceutical Chemistry (2012) and Radiopharmacy (2020) and is a pharmacist by training. Her current research focuses on the R&D of new theranostic radiopharmaceuticals with particular interest in generator-produced radionuclides. Part of her research interests also includes μ SPECT/PET/CT image analysis and interpretation. Previously she was involved in the clinical production of lutetium-177, gallium-68 and actinium-225-based theranostics in routine as well as phase I clinical trials. Janke has published 19 publications in peer-reviewed academic journals with an h-index of 9 and a total of 207 citations, as of July 2024. She currently co-supervises 3 PhD students and 2 Master's students.

Our Speakers & Panelists



○ **Olof Eriksson**, *Chief Scientific Officer Antaros Tracer*



Full professor in Drug Development and has a PhD in Radiology from Uppsala University in Sweden. He has more than 15 years' experience in preclinical and clinical research in the fields of molecular imaging and metabolic disease. He currently leads the Translational PET Imaging research group at Uppsala University which focuses on development and validation of novel PET radiopharmaceuticals. He is recipient of several large national and international grants, in total over 6.000.000 EUR. He is also co-founder and Chief Scientific Officer of the biotech start-up Antaros Tracer AB, which is developing a range of proprietary PET radiopharmaceuticals towards clinical proof-of-concept, in the fields of inflammation and fibrosis.

○ **Justin Jeffery**, *Co-Founder & Chief Innovation Officer Phantech*




Assistant director of the University of Wisconsin-Madison Carbone Cancer Center (UWCCC) Small Animal Imaging & Radiotherapy Facility (SAIRF) and has directed imaging facilities for over 15 years. He is a pioneer of the Preclinical Imaging Consortium (PIC), a meeting intended to establish best practices, standardization, and improve the efficiency and reproducibility of SAIRFs. Justin is also a co-founder of Phantech, a biomedical imaging company that designs, engineers and manufactures phantom technology (phantoms & automated software) intended for the calibration and quality management of imaging modalities including PET, SPECT, CT, MRI, FLI/BLI, MPI, radioluminescence, and theranostics/image-guided radiation therapy systems. Through these endeavors, he has co-authored 45 publications.

○ **Ingrid Yao Mattisson**, *Clinical Development Manager Spago Nanomedical*



Molecular biologist by training. She received her PhD in Experimental Medicine at Lund University Clinical Research Centre in 2019, studying immunomodulation of autoimmune mechanisms in clinical and experimental atherosclerosis. At Spago Nanomedical she is currently being responsible for the company's oncology/solid tumors and endometriosis phase I/II trials, respectively. Before moving into clinical research, Ingrid worked with nonclinical research at Spago, gaining considerable knowledge on the transition from the preclinical into the clinical phase. She also worked as a senior scientist at a preclinical CRO, contributing to the expansion of their product portfolio with new models and methods, as well as managing EU-funded projects.

Our Speakers & Panelists



○ **Thomas Wanek**, *Imaging Scientist Medizinische Universität Wien*



Head of Operation of the Preclinical Imaging Lab at the Department for Biomedical Imaging and Image-guided Therapy. He is a Bioengineer with a Ph.D. in clinical and preclinical research for drug development. During the past years, he was involved in national and international collaborative research projects with the pharmaceutical industry. His research interest focuses on ABC and SLC transporter and metabolism imaging using multimodal imaging approaches with PET and MRI. Additionally, he is interested in tumor hypoxia imaging in breast cancer using transporter-based (hENT) imaging approaches. His major scientific achievements were (1) development of a PET imaging protocol for the first time visualization of BCRP activity at the rodent blood-brain barrier, (2) development and full preclinical characterization of a novel PET tracer to assess tumor hypoxia, (3) coordination of the first European multicenter small-animal PET study to assess reproducibility and comparability of preclinical PET Data and (4) coordination and management of a national network for Correlated Multimodal Imaging in Life Science (Austrian BioImaging). He has published 87 research articles on preclinical imaging. He is a member of the Intramural Committee on Animal Experimentation of the Medical University of Vienna, the National Commission for Animal Testing Affairs, the European Society for Molecular Imaging (EMIM), and the Austrian Pharmacological Society (APHAR).

○ **Alice Zoso**, *Researcher Politecnico di Torino*




Dr. Zoso focuses on the development of *in vitro* models of fibrotic cardiac tissue based on bioartificial materials within the ERC project BIORECAR. She has a master's degree in Industrial Biotechnology at the University of Padova where she also obtained in 2014 her PhD in Bioscience and Biotechnology. From 2014 to 2017 she worked as post-doctoral fellow at the University of Geneva. Her research background are highly interdisciplinary, and span from biomedical devices and materials development to cell and molecular biology for disease modelling such as Duchenne dystrophy, Diabetes, Cystic Fibrosis and Myocardial infarction.

○ **Mattia Asti**, *Radiochemist Director AUSL-IRCCS*



Graduated with honours in Chemistry in 2001, and attained a post-graduate diploma in Laboratory Medicine, Clinical Biochemistry, and Clinical Molecular Biology with distinction from the University of Parma in 2008. He earned a Ph.D. in Biochemistry, Molecular Biology, and Biotechnology in 2013 from the University of Ferrara. By 2018, he assumed the role of Head of the Laboratory of Radiopharmaceutical Chemistry (RACHEL), overseeing all aspects of the radiopharmaceuticals preparation for clinical application and fostering research into new radiolabelled molecular entities and novel radionuclides. Recognized as a Technical Expert by the International Atomic Energy Agency (IAEA) in 2013, he has been serving as a contract professor at Ferrara University since 2011. He has significantly contributed to the development of Radiopharmaceutical Sciences in Italy and, at the moment, his main field of interest is the development of new chelators for exotic theranostic radionuclides. From 2016 to 2020, he held the position of President of the Italian Society of Radiopharmaceutical Science (GICR).

Our Speakers & Panelists



○ **Felix Gremse**, *CEO Gremse-IT*



After finishing his computer science diploma at the RWTH Aachen, Germany, Felix Gremse started his PhD at the Institut for Experiment Molecular Imaging at the RWTH Aachen University Hospital. During this time and the following time as group leader, he developed software for image analysis of preclinical and clinical multimodal image data and contributed to more than 100 scientific publications. In 2016, Felix founded his spin-out company Gremse-IT to turn the software into a product for widespread scientific usage. Gremse-IT now has offices in Aachen and Montreal with more than 20 employees which continue development and support for the software which is used at more than 100 academic and industrial sites all over the world.

○ **Syed Nuruddin**, *Senior Researcher Norsk medisinsk syklotron senter*




Preclinical Research Manager at Norwegian Medical Cyclotron Centre AS, working closely with the Radiopharmaceutical drug discovery, preclinical research and preclinical CRO business development teams. He brings in more than 10 years of experience within the radiopharmaceutical development research space. He is also affiliated as Associate Professor-II at Department of Pharmacy, University of Oslo. Syed Nuruddin is responsible for operating preclinical research lab called Oslo Imaging and Therapy laboratory (OITL). OITL supports public and private organization to perform preclinical research with Radiopharmaceutical field. Syed is veterinarian by education and has a Ph.D. from the Norwegian School of Veterinary Science, where he worked in the field of multimodal imaging and novel PET tracer development for neurodegenerative disorder.

○ **Michel Afargan**, *Head Drug Developments & Radiopharmaceutical Strategies Starget Pharma*



Michel is a seasoned drug discovery and development executive with over 25 years of experience. He has vast expertise in peptide-based drugs including medicinal chemistry, molecular biology, pharmacology, IND regulations, and pharmaceutical sciences. He was previously the Head of Pharmacology R&D at Peptor, an inventor of the phase 3 novel somatostatin analog Somatoprim® for metabolic disorders, and NET and co-inventor of the backbone-cyclization patents portfolio. He co-founded the consortium “pharmalogica” for early prediction models in drug discovery and development. He has also developed innovative, nanomedicine-based drug delivery systems and precision oncology of molecular targeting drug candidates. Michel has led multiple drug development programs resulting in IND filings and clinical trials. Michel is a leading lecturer of pharmaceutical sciences and advanced drug delivery systems at the School of Pharmacy, Hebrew University, Israel, and serves as the head of the pharmaceutical industry in the Israeli national pharmacy council. He holds a B.Sc. in Life Sciences, M.Sc. studies in Molecular Biology, B. Pharm (License) in Pharmacy., M.Sc. Pharm., and a Ph.D. at the faculties of medicine, mathematics, and life-sciences of the Hebrew University.

Our Speakers & Panelists



○ **Irving Coy Allen**, *Associate Professor-Consultant ACM*



President and Director of Research Consulting at Allen Consulting and Management. He is also the Professor of Inflammatory Diseases and the Assistant Department Head for Research Support at the Virginia Polytechnic Institute and State University where he is a faculty member appointed in both the Virginia Maryland College of Veterinary Medicine and the Virginia Tech Carilion School of Medicine. His research program is focused on translational research in the immuno-oncology space.

○ **Monique Bernsen**, *Assistant Professor Erasmus MC*




Dr. Bernsen as a PhD in Medical Biology and has been active in Molecular Imaging and Theranostics at the Erasmus MC since 2004. Her research at Erasmus MC has been focused on development and evaluation of preclinical imaging techniques for a better understanding of disease processes and for improved therapeutic options. Main research interest have included in vivo cell tracking, imaging of inflammatory processes and theranostics in oncology. In 2010 she was co-founder and chair of the preclinical imaging facility at Erasmus MC. Since 2019 she is Director of the AMIE Core Facility and in this function promotes and supports the use of imaging technology in preclinical research. To further extend this activity she has initiated the Dutch National collaborative platform AMICE, which was presented to the international community during the EMIM 2023. Within AMICE all Dutch academic, preclinical in vivo imaging facilities are united.

○ **Federico Maisano**, *Principal Scientist Bracco Imaging*



Principal Scientist of Early Stage Innovation in Bracco Global R&D. During his more than 30-year experience in the Bracco Group, he has been Scientific Advisor within the Global Bracco R&D and previously in different positions within R&D departments, including Project Leader and Biology Head. Though being chemist by education, he has extensive experience in several biology and biotechnology fields, like protein expression and purification, bioanalytical techniques, DNA and protein chemistry, immunology, immunochemistry, microscopy, biosensors as well as in imaging related fields like Magnetic Resonance Imaging, ultrasound imaging, X-ray imaging and nuclear medicine. Within this last discipline, he is leading an early-stage project aiming at a new targeted PET agent. He is author of more than 30 peer reviewed papers and about 10 patents, lecturer at several national and international conferences and reviewer for scientific journals.

Our Speakers & Panelists



○ **Pradip Chaudhari**, *Scientific Officer ACTREC*



After receiving his Bachelor of Veterinary Science and Animal Husbandry (Nagpur Veterinary College, Nagpur) he continued with a Master of Veterinary Science (1991 – 1993) in Bombay Veterinary College, Mumbai. He continued his studies at Bhabha Atomic Research Centre, Mumbai University, obtaining a diploma in Medical Radio Isotope Technology and medical radioisotope applications (1997-1998). From 2004-2008 he performed his PhD in Radiopharmaceutical Research at Mumbai University. From 1994-2007 he was the Scientific Officer of the Radiation Medicine Centre (Bhabha Atomic Research Centre) where he was involved in basic and applied nuclear medicine research, animal model development, laboratory animal science and veterinary nuclear medicine. Since 2007 he is the Scientific Officer in the Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre working with veterinary oncology, comparative oncology, preclinical imaging, animal oncology models, laboratory animal science and radiopharmaceutical research.

○ **Panagiotis Papadimitroulas**, *Co-Founder and Head of the Software Unit at BIOEMTECH*




He holds a PhD in Medical Physics and has received a Postdoctoral Research Fellowship from IKY. He specializes in Monte Carlo simulations and Artificial Intelligence techniques in medicine, with an emphasis on optimizing diagnostic and therapeutic protocols for personalized medicine. He has coordinated a European CHIST-ERA project and a project in FF4EuroHPC, while he has participated in more than 15 international and national research projects. His literature includes 3 book chapters, 30 scientific publications, and more than 70 conference presentations. He is an official member of the OpenGATE collaboration and the Hellenic Digital Health Cluster.

○ **Thodoris Karampelas**, *Partner, CSO BIOEMTECH Laboratories*



Biotechnologist by training and holds a PhD in Pharmacology. Since 2009, he has been working on research related with drug discovery and especially in the field of targeted anticancer agents. This allowed him to build critical thinking towards pharmacology as well as a strong bioanalytical background. In addition, during this period, he has established expertise regarding the different methodologies employed in all the stages of preclinical drug discovery in vitro and in vivo. Furthermore, Thodoris has experience in the setting up and maintenance of Quality Systems based on ISO17025 and good laboratory practice (GLP). He joined BIOEMTECH in 2021, where he is now the CSO, responsible for the scientific ground of the preclinical services that are running or planned in BIOEMTECH Laboratories.

Our Speakers & Panelists



- **Argyro Zacharioudaki**, *Designated Veterinarian & In-vivo Research Consultant BIOEMTECH Laboratories*



Graduated from the Veterinary Faculty of the Aristotle University of Thessaloniki, Greece. Holds a Master of Laboratory Animal Science (MLAS, University of Copenhagen) and a Postgraduate Certificate in Veterinary Education (FHEA, RVC). Qualified by examination as Diplomate of the European College of Laboratory Animal Medicine (Dipl.ECLAM) and EBVS European Veterinary Specialist in Laboratory Animal Medicine. Employed for almost 14 years as the Designated Veterinarian of the Experimental Educational Research Center ELPEN (EERCE), Athens, Greece. Currently employed as a research veterinarian and in-vivo research consultant at BIOEMTECH Laboratories, Athens, Greece. Serves as General Secretary and webmaster of Hellenic Society of Biomedical and Laboratory Animal Science (HSBLAS), and Coordinator of the LAS EU Functions Course.

- **Sophia Sarpaki**, *Project Manager BIOEMTECH Laboratories*



She obtained her BSc in Chemistry from the Chemistry Department of the Faculty of Science (University of Crete) in 2013. She continued her postgraduate studies specializing in the research and development of new generation drugs (2014) at Imperial College London and received a PhD in radiopharmaceutical chemistry (2018) from the Department of Chemistry, University of Bath. Since 2017, he has been working at BIOEMTECH as a Lead radiochemist and project manager. She has been also involved in various European or national research projects while she was the manager of 3 H2020 research projects and 2 ERANET research projects. He has 15 publications in international scientific journals and numerous announcements at international conferences.

- **Eliza Lambidis**, *R&D Radiochemist BIOEMTECH Laboratories*




Eliza has been working at BIOEMTECH since May 2022 and she is the R&D radiochemist of the company. She studied in Bath, UK, for her bachelor's degree in chemistry and completed her Master's degrees (MRes, Imperial College London, UK and MPhil, Hong Kong Baptist University, HK SAR) in chemistry and bioimaging sciences. She obtained her PhD in radiopharmaceutical chemistry from University of Helsinki, Finland, in 2022 after completing four years of individual research in the field

- **Antonis Skliris**, *In Vitro Lab Manager BIOEMTECH Laboratories*



Experienced Chemist/Biochemist with more than 13 years of scientific research and project management experience in both academia and biotechnology sector. He holds a PhD in Chemistry from University of Patras and he has been a visiting fellow in the department of translational medicine in University of Lund (Malmö, Sweden). In addition, he has performed post-doctoral research in BSRC "Alexander Fleming" (Athens, Greece) and in Tufts Medical Center (Boston, USA) in the fields of immunology, molecular oncology and neurobiology. He has authored 5 articles in peer-review journals with an H-index of 4, with more than 290 citations and >20 participations in international and national conferences (oral and poster presentations).

Notes



How to be part of our Workshop

4th Annual

BPW

**BIOEMTECH's
Preclinical Workshop**

Rates:

- € 800 Early bird (20% discount for registrations before July 15th, 2024)
- € 950 (after July 15th, 2024)
- € 750 Student (requiring student ID)

Team Discounts:

10% for 2 delegates | 20% for 3 delegates
25% for 4 or more delegates


Registration Options:

- (1) Registration [link](#) at our website
- (2) Email us at info@bioemtech.com

Venue

The Golden Age Hotel of Athens
57 Michalakopoulou str., 11528
Athens, Greece

**Hands-On Session will be held at
BIOEMTECH Laboratories**
271 Kleisthenous str., 15344,
Gerakas, Greece



*Looking forward to
expanding our horizons
together in Greece soon!*